Estimation of parameters of connective tissue metabolism at bronchoobstruction progression in patients with chronic obstructive pulmonary disease and concomitant arterial hypertension

Оценка показателей метаболизма соединительной ткани по мере прогрессирования бронхообструкции у больных хроническим обструктивным заболеванием легких и сопутствующей артериальной гипертензией
Valentina Delevskaya 1
More Detail
1 Kharkiv National Medical University, Kharkov, Ukraine
J CLIN MED KAZ, Volume 4, Issue 34, pp. 34-39.
OPEN ACCESS 3264 Views 2546 Downloads
Download Full Text (PDF)

ABSTRACT

The aim: To study the changes in connective tissue metabolism at progression of bronchoobstruction in patients with chronic obstructive pulmonary disease in combination with arterial hypertension and to determine the character of their correlations with parameters of respiratory function.
Methods: We investigated the level of serum chondroitin sulfates, glycoproteins, glycosaminoglycans and their fractional composition in 62 patients with chronic obstructive pulmonary disease of II and III degree of severity of airflow limitation with concomitant arterial hypertension.
Results: The patients had elevated serum levels of chondroitin sulfates, chondroitin-6-sulfates, glycoproteins and reduced levels of dermatan / chondroitin-4-sulfates and keratan- / heparan sulphates. While progression from II to III degree of severity of airflow limitation, along with increased levels of glycoproteins the patients had chondroitin-6-sulfates and chondroitin-4-sulfates increase and heparan sulphate decrease, that may indicate impaired synthesis of the latter type of glycosaminoglycans and expressed extracellular matrix degradation processes. Study revealed moderate and strong correlations between parameters of respiratory function, chondroitin-6-sulfates, heparan sulfates and glycoproteins may indicate their involvement in the pathogenesis of bronchial obstruction in chronic obstructive pulmonary disease and arterial hypertension.
Conclusion: Serum levels of chondroitin-6-sulfates, glycoproteins and heparan sulfates may be used in predicting bronchoobstruction progression in patients with chronic obstructive pulmonary disease and arterial hypertension.
Keywords: heparan sulphates, chondroitin-6-sulfates, chondroitin-4-sulfates, glycosaminoglycans, bronchial obstruction, arterial hypertension

CITATION

Delevskaya V. Estimation of parameters of connective tissue metabolism at bronchoobstruction progression in patients with chronic obstructive pulmonary disease and concomitant arterial hypertension. Journal of Clinical Medicine of Kazakhstan. 2014;4(34):34-9.

REFERENCES

  • Cavaillès А, Brinchault-Rabin G, Adrien Dixmier et al. Comorbidities of COPD, Eur Respir Rev, 2013, No.22(130), pp.454-75.
  • García-Olmos L, Alberquilla A, Ayala V, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study, BMC Fam Pract, 2013, No.14, pp.11.
  • Papakonstantinou E, Karakiulakis G. The ‘sweet’ and ‘bitter’ involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance, GBr J Pharmacol, 2009, No.157(7), pp.1111-1127.
  • Postma DS, Timens W. Remodeling in asthma and chronic obstructive pulmonary disease, Proc Am Thorac Soc, 2006, No.3(5), pp.434-439.
  • Suki B, Ito S, Stamenovic D, Lutchen KR, Ingenito EP. Biomechanics of the lung parenchyma: critical roles of collagen and mechanical forces, J Appl Physio, 2005, No.98(5), pp.1892-1899.
  • West JB, Mathieu-Costello O. Structure, strength, failure, and remodeling of the pulmonary blood-gas barrier, Annu Rev Physiol, 1999, No.61, pp. 543-572.
  • Rodriguez E, Roland SK, Plaas A, Roughley PJ. The glycosaminoglycan attachment regions of human aggrecan, J Biol Chem, 2006, No.281(27), pp.18444-18450.
  • Tu G, Xu W, Huang H, Li S. Progress in the development of matrix metalloproteinase inhibitors, Curr Med Chem, 2008, No.15(14), pp.1388-1395.
  • Handel TM, Johnson Z, Crown SE, et al. Regulation of protein function by glycosaminoglycans as exemplified by chemokines, Annu Rev Biochem, 2005, No.74, pp.385-410.
  • Smits NC, Shworak NW, Dekhuijzen PN, van Kuppevelt TH. Heparan sulfates in the lung: structure, diversity, and role in pulmonary emphysema, Anat Rec, 2010, No.293(6), pp.955-967.
  • Whitelock JM and Iozzo RV. Heparan sulfate: a complex polymer charged with biological activity, Chem Rev, 2005, No.105(7), pp. 2745-2764.
  • Saito A, Munakata H. Analysis of plasma proteins that bind to glycosaminoglycans, Biochim Biophys Acta, 2007, No.1770(2), pp.241-246.
  • Monzon ME, Casalino-Matsuda SM, Forteza RM. Identification of glycosaminoglycans in human airway secretions, Am J Respir Cell Mol Biol, 2006, 34(2), pp.135-141.
  • Frevert CW and Sannes PL. Matrix proteoglycans as effector molecules for epithelial cell function, Eur Respir Rev, 2005, No.14(97), pp.137–144. 
  • McAnulty RJ, Laurent GJ. Collagen synthesis and degradation in vivo. Evidence for rapid rates of collagen turnover with extensive degradation of newly synthesized collagen in tissues of the adult rat, Coll Relat Res, 1987, No.7(2), pp.93-104.
  • Laurent GJ, Chambers RC, Hill MR, McAnulty RJ. Regulation of matrix turnover: fibroblasts, forces, factors and fibrosis, Biochem Soc Trans, 2007, No.35(4), pp.647-651.
  • Papakonstantinou E, Klangas I, Kouri F, et al. Lung fibrosis is associated with a significant increase of hyaluronic acid in the lung, Eur Resp J, 2006, No.28, pp.604.
  • Logvinova O.L., Senatorova A.S. Intersticial’nye markery neblagoprijatnogo prognoza novoj formy bronholegochnoj displazii v aspekte prodolzhajushhegosja ontogeneza legkih (Interstitial markers of poor prognosis of a new form of bronchopulmonary dysplasia in terms of ongoing lung ontogenesis), Mezhdunarodnyj zhurnal pediatrii, akusherstva i ginekologii, 2013, No.4(1), pp.101-108.
  • Kapustnik V.A., Arhipkina O.L. Analiz dinamiki pokazatelej metabolicheskih izmenenij v soedinitel’noj tkani i mikrojelementnogo statusa u bol’nyh vibracionnoj bolezn’ju v sochetanii s hronicheskoj obstruktivnoj bolezn’ju legkih (Analysis of indicators of metabolic changes in the connective tissue and trace element status in patients with vibration disease combined with chronic obstructive pulmonary disease), Eksperimental’na ta klіnіchna medicina, 2009, No.4, pp.151-157.
  • Vahrushev Ja.M., Sharaev P.N., Ermakov G.I. Kliniko-metabolicheskaja ocenka jeffektivnosti bazisnoj terapii pacientov s hronicheskoj obstruktivnoj bolezn’ju legkih (Clinical and metabolic assessment of the effectiveness of the basic treatment of patients with chronic obstructive pulmonary disease), Pul’monologija, 2010, No.2, pp.65-70.
  • Scuri M, Abraham WM, Botvinnikova Y, Forteza R. Hyaluronic acid blocks porcine pancreatic elastase (PPE)-induced bronchoconstriction in sheep, Am J Respir Crit Care Med, 2001, No.164(10), pp.1855-1859.
  • Lerner I, Baraz L, Pikarsky E, et al. Function of heparanase in prostate tumorigenesis: potential for therapy, Clin Cancer Res, 2008, No.14(3), pp.668-676.
  • Campo GM, Avenoso A, Campo S, et al. Chondroitin-4-sulphate reduced oxidative injury in caerulein-induced pancreatitis in mice: the involvement of NF-kappa B translocation and apoptosis activation, Exp Biol Med, 2008, No.233(6), pp.741-752.
  • Cullmann D, Burgard G. Use of Hyaluronidase for the Prevention or Treatment of Arterial Hypertension or Cardiac Insufficiency. Patent US № 20100092450, 2010.
  • Badokin V.V. Klinicheskaja ocenka farmakologicheskoj aktivnosti preparata hondrodita sul’fat (Clinical evaluation of the pharmacological activity of the drug chondrodite sulfate), Lechashhij vrach, 2012, No.10, pp.92-95.
  • ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), J Hypertens, 2013, No.31(7), pp.1281–1357.
  • Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. http://www.goldcopd.org.
  • Sposob opredelenija geksozaminoglikansul’fatov v syvorotke krovi (A method for determining serum geksozaminoglikansulfat): a. s. 960626 SSSR, MKI3 G 09 N 23/28. M.R. Shtern, O.P. Timoshenko, F.S. Leont’eva, G.F. Kljueva.–№ 2998857/28–13; zajavl. 23.10.80; opubl. 23.09.82. Bjul. No. 35.
  • Gorjachkovskij A. M. Klinicheskaja biohimija (clinical Chemistry), Odessa,1998, 603p.
  • Levchenko V.І., Novozhits’ka Ju.M., Sahnjuk V.V. [ta іn.] Bіohіmіchnі metodi doslіdzhennja krovі hvorih. Metodichnі rekomendacії dlja lіkarіv hіmіko–toksikologіchnih vіddіlіv derzhavnih laboratorіj veterinarnoї medicini Ukraїni (Biochemical methods blood of patients. Guidelines for doctors chemical and toxicological department of state veterinary medicine laboratories Ukraine), Kiїv, Rajduga, 2004, 104 p.
  • van Straaten JF, Coers W, Noordhoek JA, et al. Proteoglycan changes in the extracellular matrix of lung tissue from patients with pulmonary emphysema, Mod Pathol, 1999, No.12, pp.697–705.